Opportunities in the Global Refractory Follicular Lymphoma Diagnostics Market include the growing need for MRD monitoring and ...

The panel discussion, “Innovations in Breast Cancer Treatment,” examined the challenge of maintaining or increasing access to care as breast cancer treatment becomes more stratified through biomarker ...

Kura Oncology holds a strong cash position with Komzifti FDA approval and frontline AML expansion potential. Read why KURA ...

In the draft guidance, the agency discusses how sponsors can leverage MRD and complete response rates as near-term efficacy measures and speed new therapies to market.

During a live event, Andrew H. Lipsky, MD, and participants discuss emerging trial data and real-world applications of ...

The FDA released a draft guidance document that provides a regulatory framework for sponsors to utilize minimal residual ...

After a short delay and concerns of potential intervention from senior officials, the FDA has issued a draft guidance for the industry on the potential use of minimal residual disease (MRD) and ...

The FDA believes that data on MRD and complete response can expedite new drug delivery compared with long-term survival ...

Pediatric acute myeloid leukemia (AML) is one of the most common acute leukemias in children. While treatment outcomes have ...

New research co-led by Indiana University School of Medicine scientists has exposed a vulnerability in acute myeloid leukemia by identifying the blood cancer's reliance on a specific signaling pathway ...

Receiving a diagnosis of Chronic Myeloid Leukemia (CML) can be frightening, but it is important to understand that the management of this disease is one of the greatest success stories in modern ...

Metastatic urothelial carcinoma has a poor prognosis: ~50% of muscle-invasive bladder cancer progresses to metastasis, and ...